BIOMAT Database Logo BIOMAT Database Logo

Complications of peptic ulcer disease before and after the introduction of H2-receptor antagonists. 1992

J Mäkelä, and S Laitinen, and M I Kairaluoma
Oulu University Central Hospital, Department of Surgery, Finland.

This study was undertaken in order to evaluate the incidence of operations for bleeding, perforated and obstructing peptic ulcers in a defined population before and after the introduction of H2-receptor antagonists. The annual incidence of surgery for all peptic ulcer complications increased slightly, from 6.9 per 10(5) individuals in 1977 to 14.2 per 10(5) in 1989 (n.s.), whereas the annual incidence of operations for ulcer bleeding and perforation remained relatively stable, varying from 2.8 to 8.9 per 10(5) inhabitants and from 2.3 to 7.5 per 10(5) inhabitants during the study period. Operations performed for gastric outlet obstruction did not increase, varying from 0.8 to 2.2 per 10(5) individuals over the study period. The annual proportion of emergency operations did not increase. Young men and old women were often operated on for bleeding (p less than 0.0001) and perforated ulcers (p less than 0.01). Duodenal ulcer bleeding and perforation were more frequent in the young patient groups. Overall mortality after operations performed for bleeding was 15%, and that after operations for perforation or obstruction, 17% and 8%, respectively. The mean age of the fatalities, 63 +/- 13 years, was significantly higher than that of those who survived after operation, 53 +/- 15 years (p 0.0001). Mortality was higher after operations for gastric ulcer complications (22%) than after operations for duodenal ulcer complications (10%) (p less than 0.01).

UI MeSH Term Description Entries
D007415 Intestinal Obstruction Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL. Intestinal Obstructions,Obstruction, Intestinal
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010438 Peptic Ulcer Hemorrhage Bleeding from a PEPTIC ULCER that can be located in any segment of the GASTROINTESTINAL TRACT. Hemorrhage, Peptic Ulcer,Peptic Ulcer Hemorrhages,Ulcer Hemorrhage, Peptic
D010439 Peptic Ulcer Perforation Penetration of a PEPTIC ULCER through the wall of DUODENUM or STOMACH allowing the leakage of luminal contents into the PERITONEAL CAVITY. Peptic Ulcer Perforations,Perforation, Peptic Ulcer,Perforations, Peptic Ulcer,Ulcer Perforation, Peptic,Ulcer Perforations, Peptic
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D004381 Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM. Curling's Ulcer,Curling Ulcer,Curlings Ulcer,Duodenal Ulcers,Ulcer, Curling,Ulcer, Duodenal,Ulcers, Duodenal
D005260 Female Females
D005387 Finland A country in northern Europe, bordering the Baltic Sea, Gulf of Bothnia, and Gulf of Finland, between Sweden and Russia. The capital is Helsinki. Aland Islands,Åland Islands
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2

Related Publications

J Mäkelä, and S Laitinen, and M I Kairaluoma
Prostaglandins, H2-receptor antagonists and peptic ulcer disease.
January 1988, Drugs,
J Mäkelä, and S Laitinen, and M I Kairaluoma
Histamine H2-receptor antagonists and peptic ulcer disease.
July 1978, Southern medical journal,
J Mäkelä, and S Laitinen, and M I Kairaluoma
Surgical treatment of peptic ulcer disease before and after introduction of H2 blockers.
July 1987, The American surgeon,
J Mäkelä, and S Laitinen, and M I Kairaluoma
[H2 receptor antagonists in the therapy of peptic ulcer disease].
August 1987, Zeitschrift fur Gastroenterologie,
J Mäkelä, and S Laitinen, and M I Kairaluoma
Incidence of perforated and bleeding peptic ulcers before and after the introduction of H2-receptor antagonists.
January 1988, Annals of surgery,
J Mäkelä, and S Laitinen, and M I Kairaluoma
The impact of H2-receptor antagonists on the complications, morbidity and mortality of peptic ulcer disease.
January 1987, Alimentary pharmacology & therapeutics,
J Mäkelä, and S Laitinen, and M I Kairaluoma
Peptic ulcer perforation before and after the introduction of H2-receptor blockers and proton pump inhibitors.
June 1997, Scandinavian journal of gastroenterology,
J Mäkelä, and S Laitinen, and M I Kairaluoma
Histamine H2-receptor antagonists in the treatment of peptic ulcer disease.
July 1988, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
J Mäkelä, and S Laitinen, and M I Kairaluoma
H2-receptor antagonists in the treatment of peptic ulcer.
February 1976, Annals of internal medicine,
J Mäkelä, and S Laitinen, and M I Kairaluoma
[Problems in ulcer surgery after the introduction of H2-receptor antagonists].
September 1992, Nihon Geka Gakkai zasshi,
Copied contents to your clipboard!